Astra pulls further ahead of Merck’s Curon project
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
Incyte goes pivotal in CDK2
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
